In June of 2024, the United States (US) Food and Drug Administration (FDA) approved Cepheid’s GeneXpert (XpertⓇHCV) for Point of Care (POC) hepatitis C (HCV) diagnostic testing, the first of its kind for HCV in the US. The test is CLIA (Clinical Laboratory Improvement Amendment) waived, meaning the instrument is simple to use and with […]
Tag Archives: Blog
On May 15, 2024, New York State hosted the second Annual Hepatitis C Elimination Progress Report virtual meeting to share progress toward reaching its elimination goals, as outlined in the 2021 release of the New York State Hepatitis C Elimination Plan. All of the materials and presentations from the May meeting are now available: Hepatitis […]
In 2022 there were 5,169 people newly diagnosed with hepatitis C (HCV) in New York State (NYS), a 9% decrease from 2021, continuing the downward trend of HCV diagnoses over the previous decade. Between 2010 and 2022, 194,375 New Yorkers were diagnosed with HCV, and of those, 53% are known to have cleared their infection […]
NYS Test4HepC Campaign to Promote Hepatitis C Screening During Pregnancy Universal hepatitis C screening among pregnant people was identified in the New York State Hepatitis C Elimination Plan as a priority for moving the state towards hepatitis C elimination by 2030. Effective May 3, 2024, New York State’s hepatitis C testing legislation will require all […]
What is the Learning Collaborative? The New York State Hepatitis C Learning Collaborative for Substance Use Disorder Treatment Programs is a two-year initiative to help programs build capacity to provide onsite HCV testing and linkage to care. The New York State Department of Health (NYSDOH) launched the first cycle of the learning collaborative on April […]
New York State (NYS) Hepatitis C (HCV) Cure Day is an annual event that provides an opportunity to celebrate those cured of HCV, encourage people to be tested, and motivate patients to initiate or continue HCV treatment. As part of these efforts, NYS features the personal stories of those impacted by HCV, and their experiences […]